Literature DB >> 2284696

Lung cancer with a single brain metastasis: therapeutic options.

A Rizzi1, M Tondini, G Rocco, G Rossi, M Robustellini, F Radaelli, C Della Pona.   

Abstract

Between January 1983 and December 1988 67 patients presenting with solitary cerebral recurrence from lung cancer were observed in our Institution. Resection was possible in 21 cases (31%). The surgical treatment included craniotomy with radical thoracotomy in 10 patients, craniotomy alone (with thoracotomy not including radical lung resection) in 5 patients and craniotomy performed within months of the initial elective thoracic surgery in 6 patients. In our series routine brain CT was carried out as a part of the staging procedure for lung cancer. Based on our results, we recommend an aggressive surgical approach to both cerebral recurrence and lung primary (scheduling craniotomy before thoracotomy), followed by whole brain RT, in order to prolong survival and improve the quality of life.

Entities:  

Mesh:

Year:  1990        PMID: 2284696     DOI: 10.1177/030089169007600614

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  13 in total

1.  The prognostic factors of lung cancer patients with brain metastases treated with radiotherapy.

Authors:  C Y Hsiung; S W Leung; C J Wang; S K Lo; H C Chen; L M Sun; F M Fang
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

2.  Solitary brain metastases from non-oat cell lung cancer: clinical and prognostic features.

Authors:  M Salvati; L Cervoni; R Delfini
Journal:  Neurosurg Rev       Date:  1996       Impact factor: 3.042

3.  Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.

Authors:  Jinwei Hu; Julia Y Ljubimova; Satoshi Inoue; Bindu Konda; Rameshwar Patil; Hui Ding; Andres Espinoza; Kolja A Wawrowsky; Chirag Patil; Alexander V Ljubimov; Keith L Black
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

4.  EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

Authors:  Shinji Shimato; Tetsuya Mitsudomi; Takayuki Kosaka; Yasushi Yatabe; Toshihiko Wakabayashi; Masaaki Mizuno; Norimoto Nakahara; Hisashi Hatano; Atsushi Natsume; Dai Ishii; Jun Yoshida
Journal:  Neuro Oncol       Date:  2006-01-20       Impact factor: 12.300

5.  Surgical resection of brain metastases from lung cancer.

Authors:  R J Andrews; D S Gluck; R H Konchingeri
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

6.  Calcium-activated potassium channels mediated blood-brain tumor barrier opening in a rat metastatic brain tumor model.

Authors:  Jinwei Hu; Xiangpeng Yuan; MinHee K Ko; Dali Yin; Manuel R Sacapano; Xiao Wang; Bindu M Konda; Andres Espinoza; Ksenia Prosolovich; John M Ong; Dwain Irvin; Keith L Black
Journal:  Mol Cancer       Date:  2007-03-14       Impact factor: 27.401

7.  Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.

Authors:  Yin-Duo Zeng; Hai Liao; Tao Qin; Li Zhang; Wei-Dong Wei; Jian-Zhong Liang; Fei Xu; Xiao-Xiao Dinglin; Shu-Xiang Ma; Li-Kun Chen
Journal:  Oncotarget       Date:  2015-04-10

8.  Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.

Authors:  Ching-Heng Lin; Kuo-Hsuan Hsu; Shih-Ni Chang; Hsi-Kai Tsou; Jason Sheehan; Meei-Ling Sheu; Hung-Chuan Pan
Journal:  Radiat Oncol       Date:  2015-06-06       Impact factor: 3.481

9.  Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1.

Authors:  Su Jin Hwang; Hye Won Lee; Hye Ree Kim; Hye Jin Song; Dong Heon Lee; Hong Lee; Chang Hoon Shin; Je-Gun Joung; Duk-Hwan Kim; Kyeung Min Joo; Hyeon Ho Kim
Journal:  Oncotarget       Date:  2015-08-21

Review 10.  MicroRNAs in brain metastases: potential role as diagnostics and therapeutics.

Authors:  Samer Alsidawi; Ehsan Malek; James J Driscoll
Journal:  Int J Mol Sci       Date:  2014-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.